Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 17/20 | 0.68 |
| ▸ | CYP17A1 | P05093 | 13/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14757482 | 0.81 | CYP3A4 (1.00) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL6127065 | 0.72 | CYP3A4 (0.65) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL4027994 | 0.71 | CYP3A4 (0.64) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL2723709 | 0.71 | CYP3A4 (1.00) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL4026634 | 0.71 | CYP3A4 (0.64) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5753124 | 0.70 | CYP3A4 (0.80) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5020196 | 0.70 | CYP3A4 (0.65) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL5755091 | 0.66 | CYP3A4 (0.56) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| SCHEMBL12253697 | 0.66 | CYP3A4 (0.59) | CYP3A4CYP17A1CYP2C9CYP2C19 | |
| Fumaric Acid SCHEMBL4029499 | 0.65 | CYP3A4 (0.58) | CYP3A4CYP17A1CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150527-B2 | Metalloenzyme inhibitor compounds | INNOCRIN PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | claimed |
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2014-10-09 | — | — | US | claimed |
| US-9150527-B2 | Metalloenzyme inhibitor compounds | INNOCRIN PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150527-B2 | Metalloenzyme inhibitor compounds | INNOCRIN PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150527-B2 | Metalloenzyme inhibitor compounds | INNOCRIN PHARMACEUTICALS, INC. (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2014-10-09 | — | — | US | disclosed |
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | INNOCRIN PHARMACEUTICALS, INC. | 2014-10-09 | — | — | US | disclosed |
| WO-2013033004-A2 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303157-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | CYP3A4 558/4885CYP17A1 649/4885CYP2C9 840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.